Cipla gets USFDA nod to market Lanreotide injection

Cipla has received approval from the US FDA to market its Lanreotide injection, a generic medication for treating acromegaly and other conditions. The product is a therapeutic equivalent of Somatuline Depot Injection, which had sales of around USD 898 million in the US for the 12-month period ending March 2024.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/aBKy3C7
via IFTTT